In the News: Microbial ID, LC-MS methods
Charles River scientists offer perspectives on the state of microbial identification and the evolution of mass spectrometry tools.
Here are links to two recently published news articles by Charles River scientists that Eureka readers might find interesting. Spying on the Bugs, which appeared this month in Contract Pharma and was written by Christine Farrance, Director of Research and Development for our Accugenix portfolio of services in Newark, Delaware, looks closely at the role environmental monitoring plays in keeping pharmaceuticals safe.
This cornerstone of a company's biological surveillance system enables companies to quickly identify organisms that pass through or live in their facilities before they have an opportunity to contaminate the entire "supply chain." Good environmental monitoring helps avoid the kinds of in-house disasters that lead to costly fines and recalls from regulatory agencies. More importantly, it helps keep the public safe from harm and instills confidence in both the company and regulators alike that the products have been properly tested. If anyone doubts the impact of good environmental monitoring, consider the flip side, when widespread contamination at New England Compounding Center triggered an outbreak of fungal meningitis that killed 64 people.
The second article, a commentary appearing this month in Bioanalysis Zone, assesses the evolution in liquid-chromatography-tandem mass spectrometry (LC-MS) in the age of big proteins. Tim Sangster, who heads up the Bioanalysis and Immunology Department for Charles River, Edinburgh, authored the commentary. The instrument of choice today is the triple quadrupole mass spectrometer – a solid and dependable instrument to support primarily qualitative work – but interest in, and applications for, other platforms is unquestionably growing, says Sangster. For those interested in learning more about recent advances in LC-MS, check out this three-part blog series on Eureka about the use of mass spectrometry tools in the development of antibody drug conjugates.